How has NeoGenomics's common stock, par value (in dollars per share) changed year-over-year?

NeoGenomics's common stock, par value (in dollars per share) decreased by 0.0% year-over-year, from $0 to $0.

NeoGenomics NEO Common stock, par value (in dollars per share)

Common stock, par value (in dollars per share) at other companies

Guardant HealthGH

——

Natera, Inc.NTRA

——

GeneDx HoldingsWGS

——

Agilent TechnologiesA

——

CareDxCDNA

——

DanaherDHR

——

Other financials

Income statement

See full

Revenue$186.7M+11.1%

Gross profit$80.9M+10.4%

Operating income-$18.2M+34.4%

Net income-$17.1M+34.0%

EPS (diluted)-$0.13+35.0%

Balance sheet

See full

Cash & equivalents$146.1M-57.8%

Total debt$66.3M+5.3%

Total equity$828.8M-6.7%

Total assets$1.3B-15.9%

Cash flow

See full

Operating cash flow-$8.1M+67.9%

CapEx$5.0M+11.1%

Free cash flow-$13.1M+56.0%

Valuation

See full

Market cap$1.68B-21.0%

Enterprise value$1.6B-5.6%

P/S2.3×-0.9×

Profitability

See full

Gross margin43.2%-1.1pp

Operating margin-14.2%+1.1pp

Net margin-13.3%+2.4pp

FCF margin-4.9%—

Returns & leverage

See full

Return on equity-11.6%+6.2pp

Debt / equity0.1×0.0×

Current ratio4.4×+2.4×

Where this comes from

Reported directly by NeoGenomics in its filing.

Tagged under the XBRL concept us-gaap:CommonStockParOrStatedValuePerShare.

The official record: NeoGenomics’s 10-Q, filed April 28, 2026, on SEC EDGAR. View the filing →

Ask your AI about NeoGenomics's common stock, par value (in dollars per share).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is NeoGenomics's common stock, par value (in dollars per share)?: NeoGenomics (NEO) reported common stock, par value (in dollars per share) of $0 in Q1 2026.
How has NeoGenomics's common stock, par value (in dollars per share) changed year-over-year?: NeoGenomics's common stock, par value (in dollars per share) decreased by 0.0% year-over-year, from $0 to $0.